Experimental in vitro, ex vivo and in vivo models in prostate cancer research
V Sailer, G von Amsberg, S Duensing, J Kirfel… - Nature Reviews …, 2023 - nature.com
Androgen deprivation therapy has a central role in the treatment of advanced prostate
cancer, often causing initial tumour remission before increasing independence from signal …
cancer, often causing initial tumour remission before increasing independence from signal …
The microRNA signatures: aberrantly expressed miRNAs in prostate cancer
N Sharma, MM Baruah - Clinical and translational oncology, 2019 - Springer
MicroRNAs (miRNAs) are short, non-coding, conserved, oligonucleotides that are regulatory
in nature and are often dysregulated in many cancers including prostate cancer. Depending …
in nature and are often dysregulated in many cancers including prostate cancer. Depending …
Exosomes derived from osteogenic tumor activate osteoclast differentiation and concurrently inhibit osteogenesis by transferring COL1A1‐targeting miRNA‐92a‐1‐5p
In patients with prostate cancer (PCa), bone lesions appear osteoblastic in radiographs;
however, pathological fractures frequently occur in PCa patients, and bone resorption is …
however, pathological fractures frequently occur in PCa patients, and bone resorption is …
Androgen deprivation causes epithelial–mesenchymal transition in the prostate: implications for androgen-deprivation therapy
Androgen deprivation is currently a standard-of-care, first-line therapy for prostate cancer in
the United States. Although this regimen effectively regresses androgen-dependent disease …
the United States. Although this regimen effectively regresses androgen-dependent disease …
Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
AM Martin, TR Nirschl, CJ Nirschl, BJ Francica… - Prostate cancer and …, 2015 - nature.com
BACKGROUND: Primary prostate cancers are infiltrated with programmed death-1 (PD-1)
expressing CD8+ T-cells. However, in early clinical trials, men with metastatic castrate …
expressing CD8+ T-cells. However, in early clinical trials, men with metastatic castrate …
Magnetic nanoparticle hyperthermia enhances radiation therapy: A study in mouse models of human prostate cancer
A Attaluri, SK Kandala, M Wabler, H Zhou… - International Journal …, 2015 - Taylor & Francis
Purpose: We aimed to characterise magnetic nanoparticle hyperthermia (mNPH) with
radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous …
radiation therapy (RT) for prostate cancer. Methods: Human prostate cancer subcutaneous …
[HTML][HTML] miR-93/miR-106b/miR-375-CIC-CRABP1: a novel regulatory axis in prostate cancer progression
Capicua (CIC) has been implicated in pathogenesis of spinocerebellar ataxia type-1 (SCA1)
neurodegenerative disease and some types of cancer; however, the role of CIC in prostate …
neurodegenerative disease and some types of cancer; however, the role of CIC in prostate …
Electrochemical aptamer-based biosensor developed to monitor PSA and VEGF released by prostate cancer cells
Early prostate cancer (PCa) diagnostic is crucial to enhance patient survival rates; besides,
non-invasive platforms have been developed worldwide in order to precisely detect PCa …
non-invasive platforms have been developed worldwide in order to precisely detect PCa …
[HTML][HTML] Molecular mechanisms and bioavailability of polyphenols in prostate cancer
T Costea, P Nagy, C Ganea, J Szöllősi… - International journal of …, 2019 - mdpi.com
Prostate cancer is the one of the most frequently diagnosed cancers among men over the
age of 50. Several lines of evidence support the observation that polyphenols have …
age of 50. Several lines of evidence support the observation that polyphenols have …
[HTML][HTML] Metabolic differences in glutamine utilization lead to metabolic vulnerabilities in prostate cancer
NM Zacharias, C McCullough, S Shanmugavelandy… - Scientific reports, 2017 - nature.com
The new oncologic paradigm of precision medicine is focused on identifying metabolic,
proteomic, transcriptomic and genomic variabilities in tumors that can be exploited to tailor …
proteomic, transcriptomic and genomic variabilities in tumors that can be exploited to tailor …